Ackrell Capital Cannabis Investment Report predicts future FDA and DEA regulatory changes
Ackrell Capital Cannabis Investment Report predicts future FDA and DEA regulatory changes The passage outlines speculative regulatory scenarios for cannabis without naming specific officials, transactions, or concrete evidence. It offers limited investigative value, low controversy, and no novel revelations about powerful actors. Key insights: Predicts FDA will create routine approval monographs for low‑THC and high‑THC cannabis extracts.; Suggests DEA will reschedule certain chemovars but not approve the flower itself.; Foresees possible federal de‑scheduling of cannabis and creation of a new federal cannabis agency.
Summary
Ackrell Capital Cannabis Investment Report predicts future FDA and DEA regulatory changes The passage outlines speculative regulatory scenarios for cannabis without naming specific officials, transactions, or concrete evidence. It offers limited investigative value, low controversy, and no novel revelations about powerful actors. Key insights: Predicts FDA will create routine approval monographs for low‑THC and high‑THC cannabis extracts.; Suggests DEA will reschedule certain chemovars but not approve the flower itself.; Foresees possible federal de‑scheduling of cannabis and creation of a new federal cannabis agency.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.